Olokizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL6 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Olokizumab is an immunomodulator. It binds to interleukin 6.[1] Hence acting as an Anti-IL-6 therapeutic aimed at inflammatory disease e.g. rheumatoid arthritis (RA).
It had promising results in a phase II trial against placebo or tocilizumab for patients with moderate to severe whan.[2][3]
Olokizumab was approved for medical use in Russia. On May 21, 2020, the Russian Health Ministry approved brand name Artlegia (olokizumab).
Olokizumab (64 mg once) is used as emergence experimental cytokine storm COVID-19 complications treatment.[4]
References
- ↑ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.
- ↑ Walsh N (6 August 2014). "RheumShorts: IL-6 and RA, Life and Death, Surgery in Lupus".
- ↑ Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, et al. (September 2014). "Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study". Annals of the Rheumatic Diseases. 73 (9): 1607–15. doi:10.1136/annrheumdis-2013-204760. PMC 4145439. PMID 24641941.
- ↑ Marrow, Alexander (8 October 2020). "Russia's R-Pharm retools arthritis drug for COVID-19 patients in clinical trial". Reuters.
External links
- "Artlegia". Russian drug reference. Medum.ru.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.